Nintedanib is a generic softgel capsule pharmaceutical product indicated for the treatment of idiopathic pulmonary fibrosis and certain types of cancers. As a tyrosine kinase inhibitor, it is designed to interfere with the cellular signaling pathways involved in fibrotic and oncological disease progression. This medication has been launched globally across 30 markets, offering sourcing buyers a standardized therapeutic option for these chronic and serious conditions.
Lotus Pharmaceutical, based in Tashkent, Uzbekistan, manufactures this product. The company was founded in 1966 and operates within the pharmaceutical product category. Buyers evaluating suppliers for generic oncology and pulmonary fibrosis treatments may consider this established manufacturer and its existing multinational market presence as part of their sourcing assessment.